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Inﬂammatory processes described in Parkinson’s disease (PD) and its animal models appear to be important in the progression
of the pathogenesis, or even a triggering factor. Here we review that peripheral inﬂammation enhances the degeneration of the
nigrostriatal dopaminergic system induced by diﬀerent insults; diﬀerent peripheral inﬂammations have been used, such as IL-1β
and the ulcerative colitis model, as well as insults to the dopaminergic system such as 6-hydroxydopamine or lipopolysaccharide.
In all cases, an increased loss of dopaminergic neurons was described; inﬂammation in the substantia nigra increased, displaying a
greatactivationofmicrogliaalongwithanincreaseintheproductionofcytokinessuchasIL-1βandTNF-α.Increasedpermeability
or disruption of the BBB, with overexpression of the ICAM-1 adhesion molecule and inﬁltration of circulating monocytes into
the substantia nigra, is also involved, since the depletion of circulating monocytes prevents the eﬀects of peripheral inﬂammation.
Data are reviewed in relation to epidemiological studies of PD.
1.Introduction
Parkinson’s disease (PD) is the second most common aging-
related neurodegenerative disease after Alzheimer’s disease
(AD). The main symptom of PD is a movement disorder
called Parkinsonism (muscle rigidity, akinesia, and resting
tremor) caused by dopamine (DA) deﬁciency in the striatum
due to DA neuron degeneration in the substantia nigra
(SN). Although a small percentage of PD is familial (fPD),
most is sporadic (sPD), associated with aging and with no
hereditary history. Aetiology of PD probably involves both
environmental agents and genetic risk factors [1–3]. The
implication of inﬂammatory process in PD is accepted, since
many inﬂammatory marks have been described in PD and
its animal models (for a review of neuroinﬂammation in PD,
see [4]). Consequently, neuroinﬂammation is now thought
to be fundamental for, or even a triggering factor of, the
progression of PD pathogenesis.
Activated microglia and reactive human leukocyte
antigen-DR (HLA-DR)-positive microglia were found in
the SN pars compacta (SNpc) [5, 6] in the postmortem
analysis of PD patients. Immunohistochemical studies have
shown many activated microglial cells in neurotoxin-treated
SNpc in various animal PD models [7], suggesting the
presence of inﬂammatory processes [8–12]. Moreover, levels
of proinﬂammatory substances such as cyclooxygenase 2
(COX2) and cytokines including interleukine-1 beta (IL-
1β),interferon-gamma(IFN-γ),andtumournecrosisfactor-
alpha (TNF-α), are found to be high in postmortem PD
brains [13–17]. Similarly, 6-hydroxydopamine (6-OHDA)
and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
animal PD models showed increased levels of these
inﬂammatory mediators [10, 18–21], which are secreted
from microglia, neurons, and astrocytes [22–25]. There-
fore, these molecules may be actively involved in disease
progression.2 Parkinson’s Disease
Several studies have tried to correlate polymorphisms
in the promoters of several cytokine genes to the risk of
developing PD [26–31]. Pattarini et al. [32] have shown
protectionagainstMPTPtoxicity-measuredasattenuationof
dopamine depletion in the striatum-after genetic ablation of
either TNF-α or its receptors Tnfrsf1 and Tnfrsf2 [18, 21, 33,
34], although neither genetic ablation nor pharmacological
manipulation of TNF-α prevents neuronal loss in the SNpc
[18, 35, 36]. On the contrary, Il-6 knockout mice are
more sensitive to MPTP toxicity [37], which could be in
agreement with the neuroprotective eﬀect described for IL-
6[ 38]. Clinical studies on chronic users of nonsteroidal
anti-inﬂammatory drugs (NSAIDs) suggest that some of
these agents could lower the incidence of PD [39–42].
However, no such association was found in other studies
[43, 44], although this preventive eﬀect has been described
in experiments with animals [45–47]. In the MPTP model
of PD [48], the inactivation of microglia also showed to be
neuroprotective.
Animal models of degeneration of the nigrostriatal
dopaminergic system have been developed by intranigral
injection of proinﬂammogens [11, 49–60]. Furthermore,
other features support the implication of inﬂammation in
the development or progression of PD. Chronic traumatic
brain injury associated with boxing has been etiologically
linked to PD with the well-known “punch-drunk syndrome”
or “dementia pugilistica” that sometimes develops in boxers
asaresultoflong-termsubclinicalconcussions[61–66].This
is in agreement with the fact that inﬂammation through
microglial activation accompanies the CNS tissue’s response
to injury (for review see Loane and Byrnes [67]).
The brain is considered an immunologically privileged
organ, free from immune reactions, since it is protected
by the blood-brain barrier (BBB). However, accumulating
ﬁndings have revealed that immune responses can occur
in the brain, especially because of microglial activation.
Thesecellsareknowntoproduceproinﬂammatorycytokines
and a relationship with the peripheral system has been
suggested. Moreover, it is known that neurovascular func-
tions are altered in aging and neurodegenerative diseases,
leading to abnormal states such as increased BBB perme-
ability, decreased nutrient supply, faulty clearance of toxic
molecules, and failure of enzymatic function [68]. Moreover,
several studies on PD patients and animal models suggest a
pathogenic link between BBB disruption and DA neuronal
death. Positron emission tomography (PET) and histological
studies on PD patients revealed dysfunction of the BBB
transport system [69] as well as alteration of blood vessels
in the midbrain of PD patients [70]. In addition, levels
of vascular endothelial growth factor (VEGF) and pigment
epithelium-derived factor (PEDF) that induce structural
changes in blood vessels were higher in PD patients and
the MPTP model [71]. Interestingly, injecting VEGF in
the SN disrupted BBB and induced DA neuronal death
in the ventral mesencephalon [72]. In addition, increased
BBB permeability was observed in the MPTP [73]a n d
lipopolysaccharide (LPS) models of PD [74]. These results
indicate that BBB disruption is somehow related to neuronal
cell death and neuroinﬂammation in PD. Moreover, the
presence of T lymphocytes in the midbrain of PD patients
suggests that the potential role of inﬁltrated peripheral cells
is related to the pathogenesis of PD [75]. In the model
of LPS-induced inﬂammation, neutrophils and monocytes
inﬁltrate into the SN region, where they play an important
roleinneuroinﬂammation[76].Brochardetal.[77]reported
that many CD4- and CD8-positive cells were detected
postmortem in PD patients. In particular, the cytotoxic
eﬀects of T cells showed that CD4-deﬁcient mice were
resistant to MPTP neurotoxicity in the SN. In addition, the
presence of Iba-1 positive cells in disrupted blood vessels
indicates that neuroinﬂammation might contribute to the
inﬁltration of peripheral immune cells and leakage of the
BBB in the SN. Taken together, these results suggest that
penetration of immune cells plays an important role in the
degeneration of DA neurons in PD.
Peripheral inﬂammation could also have consequences
on the degenerative process of DA neurons. There are many
pathological circumstances in which peripheral inﬂamma-
tion is a common symptom. Epidemiological studies have
shown that incidence of idiopathic PD is about 50% lower
in chronic users of NSAIDs or COX inhibitors than in
age-matched nonusers [39, 40, 78]. This could be related
to inﬂammation inhibition in the CNS, but also to the
inhibition of peripheral inﬂammation. Moreover, the role
of peripheral inﬂammation in diﬀerent neurodegenerative
diseases has become evident in recent years. The probability
of suﬀering AD doubles in elderly individuals exposed to
systemic inﬂammation [79]. Furthermore, induction of a
systemicinﬂammatoryresponseledtoreactivationinanimal
models of multiple sclerosis [80]. Strang [81]d e s c r i b e d
the increased prevalence of peptic ulcer prodromal to idio-
pathic Parkinsonism. This was independently produced by
Helicobacter or not [82]. Systemic inﬂammation sensitized
microglia to switch to an overactivated proinﬂammatory
state in a model of prion disease [83]. Here, we review the
possibility that peripheral inﬂammation could enhance the
degeneration of the nigrostriatal dopaminergic system and
thus it would be involved in the incidence of PD.
2. Inﬂammation Increases
the Degeneration of the Dopaminergic
System Induced by an Insult
First, we must note that inﬂammation is capable of increas-
ing the degeneration of the dopaminergic system induced by
diﬀerent insults.
2.1. In Vitro Studies. Gao et al. [84, 85] have shown that low
doses of neurotoxin (rotenone or MPTP) and inﬂammogen
LPSsynergisticallyinducedaprogressiveandselectivedegen-
eration of dopaminergic neurons in mesencephalic neuron-
glia cultures. They showed that glia is required for this eﬀect;
in addition, they also showed that the eﬀect was produced
by a synergistic increase in NO and the superoxide free
radical produced by NADPH oxidase. Similar results were
described by Long-Smith et al. [86] using the cytokine-
rich conditioned medium (CM) from LPS-treated ratParkinson’s Disease 3
glial-enriched cortical cultures and 6-OHDA. They also
showed that IL-1β in the CM mediated the increase in
neuronal death since IL-1 receptor (IL-1R1) was located
in dopaminergic neurons and its blockade prevented this
eﬀect. However, the authors also pointed out that many
o t h e rc y t o t o x i cf a c t o r ss u c ha sT N F - α—and indeed some
cytoprotective ones, may also be in the medium. Zhang et
al. [87] also showed that combinations of MnCl2 and LPS, at
minimallyeﬀectiveconcentrationswhenusedalone,induced
synergistic and preferential damage to DA neurons in rat
primary neuron-glia cultures. These authors also showed
that this eﬀect could be produced by a signiﬁcant increase in
TNF-αandIL-1βreleasealongwiththeincreasedproduction
of reactive oxygen species (ROS) and NO. These eﬀects were
attenuated by pretreatment with anti-inﬂammatory agents,
such as minocycline and naloxone.
2.2. In Vivo Studies.. K o p r i c he ta l .[ 88] induced a nontoxic
inﬂammation in the SN, injecting a non-DA-toxic dose of
LPS within the SN followed by injecting a low dose of 6-
OHDA in the striatum, demonstrating that dopaminergic
cell loss increased signiﬁcantly. The authors identiﬁed IL-
1β as a potential mediator of the eﬀe c t ,a n dw e r ea b l et o
overcomeitbytheadministinganIL-1R1antagonist.Similar
results have been also described by Godoy et al. [19]w h o
used a similar method, also showing that inﬂammation
induced by a low dose of LPS in SN produced a signiﬁcant
increase in the degeneration of DA neurons in SN induced
by 6-OHDA compared with 6-OHDA alone. Moreover, this
eﬀectwasovercomebydexamethasone(DEX),awell-known
anti-inﬂammatory steroid. These results show that inﬂam-
mation is able to enhance the degeneration of dopaminergic
neurons induced by several insults.
3. Peripheral Inﬂammation Enhances
the Degeneration of the Nigrostriatal
DopaminergicSystem
It is important to know whether peripheral inﬂammation, a
very common health problem, could aﬀect the degeneration
of nigrostriatal dopaminergic neurons. Godoy et al. [19]
induced a peripheral-like inﬂammatory state by injecting
an adenoviral vector expressing IL-1β (or β-galactosidase
as control) in the tail vein. This model was used to study
the eﬀect of peripheral inﬂammation on the nigrostriatal
dopaminergic neurodegeneration induced by injecting 6-
OHDA in the striatum. The authors found a statistically
signiﬁcant decrease in the number of TH-positive cells in
the SN of the animals treated with 6-OHDA/Ad IL1biv in
comparison with the other groups. These data showed that
systemic IL-1 expression exacerbates, but does not directly
elicit, neurodegeneration in the SN. This eﬀect is produced
byanincreaseininﬂammationinSNashasbeenpointedout
by the great reactivation of microglia (stage 4 morphology)
found along with other parameter studies. This is the ﬁrst
description of the inﬂuence of peripheral inﬂammation
on the degeneration of nigrostriatal dopaminergic system
induced by an insult (6-OHDA). Similarly, Mangano and
Hayley [89], injecting low amounts of LPS in the SN and
the administration of the pesticide paraquat (which has been
reported to provoke DA loss) showed a greater loss of TH-
positive neurons in SN after two days.
Villar´ an et al. [90] studied the eﬀect of peripheral
inﬂammation on the degeneration of the nigrostriatal
dopaminergic system induced by injecting LPS within the
SN. The Ulcerative Colitis model (UC, one of the two
major forms of gastrointestinal dysfunction) induced by
dextran sodium sulphate (DSS) [91] was used as peripheral
inﬂammation model; dextran sulphate provides an easy
and well-characterized model that shares most features
of human UC at structural, ultrastructural and clinical
levels [92], including peripheral inﬂammation. The authors
found a decrease in the number of TH-positive neurons in
the animals with LPS-treated UC, doubling that found in
animalstreatedwithLPS.Theseresultsareinagreementwith
those described by Pott Godoy et al. [93], who studied the
eﬀect of peripheral inﬂammation (intravenous injection of
adenovirus expressing IL-1β or β-galactosidase) on central
inﬂammation (injecting adenovirus expressing IL-1β into
the striatum). They found that chronic, systemic IL-1β
expression exacerbated the neurodegeneration induced by
IL-1β expression in the SN.
4. Mechanisms by Which Peripheral
Inﬂammation Could Enhance
the Degeneration of the Nigrostriatal
Dopaminergic SystemInduced byInsults
As has been described by Gao et al. [84, 85] in studies
using primary mesencephalic neuron-glia cultures as in
vitro model of PD, participation of microglia is required
for the induction of the synergistic neurotoxicity induced
by inﬂammation (LPS) on the toxic eﬀect of MPTP or
rotenone. This suggests that inﬂammation (as the reactiva-
tion of microglia and secretion of many proinﬂammatory
compounds) could be the cause of the synergistic process.
In this context, they described that the release of superoxide
free radical and the production of intracellular ROS was
synergistic. Since this eﬀect does not occur when NADPH
oxidase-deﬁcient (gp91phox−/−) mice were used, they
also showed that it was catalyzed by NADPH oxidase, an
enzyme that seems to be a major source of extracellular
superoxide production in microglia. This proposal is in
agreement with Godoy et al. [19] who described that stage
4 microglia and MHC II expression were associated with the
exacerbation of neurodegeneration and motor symptoms.
Similarly to Koprich et al. [88], these authors proposed
that microglial activation towards a proinﬂammatory phe-
notype that increases IL-1β secretion is responsible for the
synergistic eﬀect. They pointed out that IL-1β is the cause
of this eﬀect, since glucocorticoid treatment and speciﬁc
IL-1 inhibition overcome these eﬀects. This proposal is
also supported by an in vitro study in which IL-1 directly
exacerbated 6-OHDA-triggered dopaminergic toxicity. This
is also supported by Koprich et al. [88], who showed that
the systemic administration of IL-1ra was able to reverse4 Parkinson’s Disease
the vulnerability produced by LPS and therefore eliminate
the contribution of 6-OHDA to DA cell death. This is in
agreement with Godoy et al. [19], who also proposed that
IL-1β is responsible for the synergistic eﬀect seen in the
animal model of chronic systemic inﬂammation produced
by injecting an adenoviral vector expressing IL1β (or β-
galactosidase as control) in the tail vein. They concluded that
IL-1β could be acting directly on neurons, and also indirectly
through NO. Furthermore, this is also in agreement with
Ferrari et al. [94], who showed that chronic expression of
IL-1β in adult rat SNpc using a recombinant adenovirus
caused the death of dopaminergic neurons after three weeks.
Mangano and Hayley [89] also suggested that the increase
in inﬂammatory cytokines IL-6, IL-2, TNF-α,a n dI F N - γ
was responsible for this eﬀect. Villar´ an et al. [90] showed
that the loss of TH-positive neurons induced in UC-LPS
animals was produced along with a signiﬁcant increase in
microglial activation, and almost doubled that produced in
animals treated with LPS alone. Moreover, it is worth noting
that the authors found a signiﬁcant increase in many of the
cytokines studied in the animals with UC, such as TNF-α,
IL-1β, and IL-6. This eﬀect was increased in the UC-LPS
animals. These results could be in agreement with Godoy
et al. [19], especially regarding the increase in cytokines, in
spite of their being unable to distinguish the eﬀect of each
in relationship to the degeneration of DAergic neurons. In
this work, the authors also found a signiﬁcant increase in
inducible nitric oxide synthase (iNOS), which could also be
involved in the eﬀect of peripheral inﬂammation, which in
turn could be in agreement with Cunningham et al. [83]
who found that IL-1 could exacerbate disease symptoms in
a prion disease model. Moreover, the relationship between
these cytokines is worth noting. Koprich et al. [88]d e s c r i b e d
that their model’s suppression of LPS sensitivity, produced
by the systemic treatment with IL-1ra, also produced a
reduction in the levels of the proinﬂammatory cytokines
IFN-γ and TNF-α in the SN, supporting the cross-regulation
between them, as had been previously pointed out. TNF-
α is also toxic to DA neurons when injected into the rat’s
brain, but the toxicity is greater when TNF-α and IL-1β
were injected together [95]. A study using IL-1β and TNF-
α-neutralizing antibodies showed that approximately 50% of
the LPS-induced DA neuronal cell death in primary cultures
of rat midbrain was mediated by the production of these
two cytokines [96]. The implication of TNF-α signalling in
the destruction of SN DA neurons in animal models of PD
have also been reported [18, 21, 36, 97]. Moreover, TNF-α
contributed to the nigrostriatal neurodegeneration provoked
by several DA insults [18, 21, 33, 34, 48, 98, 99]. Recently,
De Lella Ezcurra et al. [100] have reported that chronic
expression of low levels of TNF-α by adenoviral expression
in the SN elicits progressive neurodegeneration, delayed
motor symptoms and microglia/macrophage activation. All
these data suggest that the increase in the inﬂammatory
parameters in the periphery (blood) as a result of peripheral
inﬂammation induced the increase in inﬂammation in SN
and consequently the synergistic eﬀect on the nigrostriatal
dopaminergic system. The mechanism is not well known,
but it is possible to suggest that at least some of these
cytokines could enter. Circulating IL-1β may activate central
neurons in a direct manner, especially in regions where BBB
is deﬁcient [101]. Furthermore, blood-borne IL-1β seems
to stimulate the synthesis of prostaglandin E2 in central
vessels, which can then diﬀuse into brain parenchyma to
activate neurons in the SNC [102]. It should be also taken
into account that the increase in BBB permeability, as well
as its rupture, has been described as consequence of some
peripheralinﬂammatoryprocesses;so,disruptionoftheBBB
has been described during TBS colitis [103, 104]. Reyes
et al. [105] have shown that peripheral thermal injuries
produced an increase in BBB permeability and rupture. In
vitro, these eﬀects have been proved to be produced by
TNF-α,I L - 1 β, and IL-6 through the COX pathway [106]. In
vivo, upregulation of TNF-α and IL-1β,a sw e l la sp r o m o t e d
blood-borne inﬂammatory cell adherence and inﬁltration,
mayberesponsible[107–109].Manystudieshaveshownthat
cytokinesmayplayanimportantroleinthealterationofBBB
function [109–112] .T h e r ei sn oa g r e e m e n ti nt h er e p o r t so n
rupture or increased permeability of the BBB in PD [113–
115]. However, PET and histological studies on PD patients
have shown dysfunction in the BBB transporter system [69]
and alteration of blood vessels [70] in the midbrain of PD
patients. Additionally, the levels of VEGF and PEDF that
induce structural changes in blood vessels increased in PD
patients and the MPTP model [71]. Moreover, Rite et al. [72]
showed disrupted BBB and induced DA neuronal death in
the ventral mesencephalon after injecting VEGF within the
SN.Allthesedataallowustosuggestthatthesecircumstances
could favour conditions in which peripheral cytokines were
able to enter the CNS.
The degenerative processes of the nigrostriatal DAergic
system in PD could be related to McGeer’s description of a
massivenumberofcytotoxicTcells(Tc)intheSNofpatients
with PD [75], along with descriptions that the density of
IFN-γ-positivecellswasmarkedlyhigherinbrainsofpatients
with PD [116]. Both facts suggest that the recruitment of T
cells to the brain could be associated with the nigrostriatal
pathway injury in PD. This possibility has been conﬁrmed
by Brochard et al. [77], who described that CD8+ and
CD4+ T cells, but not B cells, invaded the brain during
the course of neuronal degeneration in the MPTP animal
model of PD. The eﬀect of these cells was reinforced by the
fact that the MPTP-induced dopaminergic cell death was
markedlyattenuatedintheabsenceofmatureTlymphocytes
in two diﬀerent immunodeﬁcient mice strains (Rag1−/−
and Tcrb−/− mice). However, there was no protection
in mice lacking CD8. The implication of these cells was
strongly supported, since the authors also found that both
CD8+ and CD4+ T cells accumulated markedly in the SNpc
of PD patients. These data indicate that T cell-mediated
dopaminergic toxicity is almost exclusively mediated by
CD4+Tcells.Theauthorsalsopointoutthatthelymphocyte
inﬁltration into the brain is not a passive phenomenon,
suggesting that the activation of microglia along innate
neuroinﬂammatory processes with the modiﬁcation of the
local microenvironment could be involved. They found
the upregulated expression of the intercellular adhesion
molecule-1 (ICAM-1) adhesion molecule on both capillariesParkinson’s Disease 5
and glial cells, which may participate in the attachment of
leukocytes to the vascular endothelium and their diapedesis
[117]. In this context, Villar´ an et al. [90] has shown the
eﬀect of peripheral inﬂammation (UC) on the inﬁltration
of circulating monocytes in the SN using ﬂow cytometry
analyses. They found that monocytes inﬁltration into the SN
increased in the UC-LPS animals compared with the animals
treated with LPS alone. Moreover, they showed the reversion
of most of the deleterious eﬀects of peripheral inﬂammation
on microglial activation, BBB disruption, astrocytes loss,
and degeneration of nigral dopaminergic neurons induced
by LPS after using clodronate encapsulated in liposomes
(ClodLip), which produced a peripheral macrophage deple-
tion lasting 5 days in blood, liver, and spleen of normal rats
and mice [118–120]. Taken together, these results suggest
that peripheral inﬂammation induced by UC contributes to
dopaminergic degeneration; the activation of macrophages
seems to play some role, since the destruction of this
peripheralleukocytetypebyClodLipabolishesthedamaging
eﬀects associated with UC in the ventral mesencephalon.
Brochard et al. [77] suggested that the overexpression of
the ICAM-1 adhesion molecule could be involved in the
active migration of these cells. Villar´ an et al. [90] also found
a signiﬁcant increase in ICAM-1 in the SN of UC-LPS
animals. It is also interesting to note that the overexpression
of ICAM-1 was also described in the SN of patients with
PD and in MPTP-intoxicated monkeys [121], supporting a
role for immune regulation outside the CNS and the possible
implication of peripheral inﬂammation.
All these data show that peripheral inﬂammation could
enhance the degeneration of the nigrostriatal system, previ-
ously induced by an insult. Therefore, PD symptoms could
appear earlier, increasing the incidence of the disease. An
increased prevalence of peptic ulcer prodromal to idiopathic
Parkinsonism has been described [81, 122]. This prompted
some authors to suggest a prominent role of inﬂammation in
the gastrointestinal tract in the aetiology and pathogenesis
of idiopathic Parkinsonism, including a possible role for
Helicobacter pylori infections [82, 123]. This infective process
is the most prevalent in the world, aﬀecting approximately
50% of the population [124], and it is considered the
causative agent of many gastrointestinal and extradigestive
conditions. Colonization of gastric mucosa by H. pylori is
accompanied by an inﬂammatory response associated with
gastric mucosal damage through the activation of polymor-
phonuclear neutrophil leukocytes [125] and inﬂammatory
inﬁltration of lymphocytes, plasma cells, and macrophages
in the stomach tissue [126–128]. Also described was the
production of proinﬂammatory factors such as IL-8, IL-1,
and TNF-α [115, 129, 130].
It should not be ignored that a high peripheral inﬂam-
mation could induce the degeneration of the nigrostriatal
system alone and also that peripheral inﬂammation could
produce a special sensitivity to other dopaminergic insults.
An increase in PD was reported following the Spanish ﬂu
in 1918 [131]; however, the viral RNA is reported absent
from brain samples of encephalitis lethargica patients from
1916 to 1920 [132]. It is conceivable that the massive
immune response or “cytokine storm” [133] created by the
virus initiated inﬂammation in the CNS; also, the great
peripheralinﬂammationcouldhaveaﬀectedthenigrostriatal
dopaminergic neurons. The inﬂammation produced by a
single injection of a large dose of LPS into the periphery
has been shown to produce inﬂammation in the brain,
resulting in signiﬁcant DA neuron loss in the SN [134].
Villar´ an et al. [90] also reported a decrease in TH positive
neurons in the SN in animals with UC after injecting vehicle
within this structure. The speciﬁc sensitization was reported
by Ling et al. [135], who showed that prenatal exposure
to LPS increased DA cell loss following adult exposure to
6-OHDA.
5. Conclusions
Our aim was to point out that inﬂammation is able to
enhance the damage to DAergic neurons and, more impor-
tantly, that peripheral inﬂammation is also able to produce
a synergistic increase in the eﬀect produced by any insult in
the nigrostriatal dopaminergic system, resulting in a greater
loss of DA neurons. Consequently, this eﬀect increases the
progressionrateofPD.Theeﬀectofperipheralinﬂammation
seems to be produced through a signiﬁcantly increased
inﬂammation in the SN. This could be produced by some of
the cytokines that increase in blood, such as IL-β and TNF-
α, directly or indirectly through its transport to the CNS
(SN). Moreover, these eﬀects could be also accompanied by
the recruitment of peripheral monocytes that also directly
increasetheinﬂammationprocessintheSN.Theimplication
of peripheral inﬂammation could explain some epidemio-
logical data on the incidence of PD, and probably also the
eﬀect of chronic anti-inﬂammatory treatments. These eﬀects
should be taken into account in the progression of PD.
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